CN101275142A - 新城疫病毒感染性克隆、疫苗及诊断分析 - Google Patents
新城疫病毒感染性克隆、疫苗及诊断分析 Download PDFInfo
- Publication number
- CN101275142A CN101275142A CNA2008100921449A CN200810092144A CN101275142A CN 101275142 A CN101275142 A CN 101275142A CN A2008100921449 A CNA2008100921449 A CN A2008100921449A CN 200810092144 A CN200810092144 A CN 200810092144A CN 101275142 A CN101275142 A CN 101275142A
- Authority
- CN
- China
- Prior art keywords
- ndv
- virus
- cdna
- vaccine
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711404 Avian avulavirus 1 Species 0.000 title claims abstract description 319
- 229960005486 vaccine Drugs 0.000 title claims abstract description 125
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 87
- 230000002458 infectious effect Effects 0.000 title claims abstract description 56
- 238000003556 assay Methods 0.000 title abstract 2
- 239000002299 complementary DNA Substances 0.000 claims abstract description 111
- 238000000034 method Methods 0.000 claims abstract description 76
- 241000700605 Viruses Species 0.000 claims description 173
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 241000271566 Aves Species 0.000 claims description 68
- 239000002773 nucleotide Substances 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 238000011081 inoculation Methods 0.000 claims description 42
- 238000005336 cracking Methods 0.000 claims description 39
- 238000012360 testing method Methods 0.000 claims description 37
- 244000144977 poultry Species 0.000 claims description 27
- 206010014599 encephalitis Diseases 0.000 claims description 25
- 238000001890 transfection Methods 0.000 claims description 25
- 241000287828 Gallus gallus Species 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 230000001717 pathogenic effect Effects 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000012530 fluid Substances 0.000 claims description 21
- 230000004048 modification Effects 0.000 claims description 21
- 238000012986 modification Methods 0.000 claims description 21
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 18
- 208000010359 Newcastle Disease Diseases 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 16
- 230000003308 immunostimulating effect Effects 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000002797 proteolythic effect Effects 0.000 claims description 9
- 108010067390 Viral Proteins Proteins 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000008034 disappearance Effects 0.000 claims description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000001018 virulence Effects 0.000 abstract description 26
- 239000003550 marker Substances 0.000 abstract description 22
- 238000012239 gene modification Methods 0.000 abstract description 18
- 230000005017 genetic modification Effects 0.000 abstract description 18
- 235000013617 genetically modified food Nutrition 0.000 abstract description 18
- 230000008569 process Effects 0.000 abstract description 14
- 238000012217 deletion Methods 0.000 abstract description 8
- 230000037430 deletion Effects 0.000 abstract description 8
- 238000003780 insertion Methods 0.000 abstract description 8
- 230000037431 insertion Effects 0.000 abstract description 8
- 230000002238 attenuated effect Effects 0.000 abstract description 5
- 230000000890 antigenic effect Effects 0.000 abstract description 3
- 230000035772 mutation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 151
- 239000013612 plasmid Substances 0.000 description 151
- 238000003752 polymerase chain reaction Methods 0.000 description 82
- 239000012634 fragment Substances 0.000 description 60
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 52
- 150000001413 amino acids Chemical class 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 32
- 201000010099 disease Diseases 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 230000029087 digestion Effects 0.000 description 29
- 101150008820 HN gene Proteins 0.000 description 27
- 101710137500 T7 RNA polymerase Proteins 0.000 description 25
- 235000013594 poultry meat Nutrition 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 21
- 235000013330 chicken meat Nutrition 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000013467 fragmentation Methods 0.000 description 20
- 238000006062 fragmentation reaction Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 description 18
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 18
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 17
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 14
- 235000019419 proteases Nutrition 0.000 description 14
- 230000004087 circulation Effects 0.000 description 12
- 210000002345 respiratory system Anatomy 0.000 description 12
- 238000010839 reverse transcription Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 101150062031 L gene Proteins 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 229940031551 inactivated vaccine Drugs 0.000 description 10
- 101150012509 sub gene Proteins 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 241000700662 Fowlpox virus Species 0.000 description 8
- 108020000999 Viral RNA Proteins 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000002405 diagnostic procedure Methods 0.000 description 8
- 230000008521 reorganization Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 6
- 108010061982 DNA Ligases Proteins 0.000 description 6
- 208000037262 Hepatitis delta Diseases 0.000 description 6
- 241000724709 Hepatitis delta virus Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000009849 deactivation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 241000272525 Anas platyrhynchos Species 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 101150034814 F gene Proteins 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 241001430197 Mollicutes Species 0.000 description 5
- 101100473971 Mus musculus Pdcd11 gene Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- 101100030133 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SEC53 gene Proteins 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000008676 import Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 4
- 101001081170 Homo sapiens Humanin-like 12 Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 102100027737 Humanin-like 12 Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 241000286209 Phasianidae Species 0.000 description 4
- 241000607479 Yersinia pestis Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000009361 aviculture Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 3
- 241000712083 Canine morbillivirus Species 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241001559187 Human rubulavirus 2 Species 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 241000711504 Paramyxoviridae Species 0.000 description 3
- 101710086015 RNA ligase Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 238000005844 autocatalytic reaction Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000013326 plasmid cotransfection Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 2
- 241001493169 Avian avulavirus 2 Species 0.000 description 2
- 241001135673 Avian avulavirus 4 Species 0.000 description 2
- 241000713826 Avian leukosis virus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000725585 Chicken anemia virus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 241000702626 Infectious bursal disease virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 2
- 101150118742 NP gene Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 101100065137 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prt-1 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000272458 Numididae Species 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 208000027954 Poultry disease Diseases 0.000 description 2
- 241000287531 Psittacidae Species 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 241000711897 Rinderpest morbillivirus Species 0.000 description 2
- 241001533467 Rubulavirus Species 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100038126 Tenascin Human genes 0.000 description 2
- 108010008125 Tenascin Proteins 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001707 blastogenic effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000011331 genomic analysis Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000001894 hemadsorption Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 241000588813 Alcaligenes faecalis Species 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108700040077 Baculovirus p10 Proteins 0.000 description 1
- 241000588851 Bordetella avium Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000272205 Columba livia Species 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- 102100029068 Humanin-like 4 Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 241000711513 Mononegavirales Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100285899 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSE2 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 101900072274 Sendai virus Protein V Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- -1 Streptomycin sulphates Chemical class 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- YIABPNNTABODQB-UHFFFAOYSA-L [Co](Cl)Cl.C(CCCCC)N Chemical compound [Co](Cl)Cl.C(CCCCC)N YIABPNNTABODQB-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 229940005347 alcaligenes faecalis Drugs 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229940030547 autologous tumor cell vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 208000027889 monkey disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- IZRPKIZLIFYYKR-UHFFFAOYSA-N phenyltoloxamine Chemical compound CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 IZRPKIZLIFYYKR-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98202054A EP0974660A1 (en) | 1998-06-19 | 1998-06-19 | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| EP98202054.7 | 1998-06-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99809714A Division CN1314942A (zh) | 1998-06-19 | 1999-06-17 | 新城疫病毒感染性克隆、疫苗及诊断分析 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101275142A true CN101275142A (zh) | 2008-10-01 |
Family
ID=8233832
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100921449A Pending CN101275142A (zh) | 1998-06-19 | 1999-06-17 | 新城疫病毒感染性克隆、疫苗及诊断分析 |
| CN99809714A Pending CN1314942A (zh) | 1998-06-19 | 1999-06-17 | 新城疫病毒感染性克隆、疫苗及诊断分析 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99809714A Pending CN1314942A (zh) | 1998-06-19 | 1999-06-17 | 新城疫病毒感染性克隆、疫苗及诊断分析 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6719979B2 (enExample) |
| EP (2) | EP0974660A1 (enExample) |
| JP (3) | JP2002518012A (enExample) |
| KR (1) | KR20010053000A (enExample) |
| CN (2) | CN101275142A (enExample) |
| AR (1) | AR020091A1 (enExample) |
| AT (1) | ATE367442T1 (enExample) |
| AU (1) | AU754844B2 (enExample) |
| BR (1) | BR9911383A (enExample) |
| CA (1) | CA2334165A1 (enExample) |
| CZ (1) | CZ300760B6 (enExample) |
| DE (1) | DE69936585T2 (enExample) |
| DK (1) | DK1088077T3 (enExample) |
| EA (1) | EA004796B1 (enExample) |
| ES (1) | ES2291029T3 (enExample) |
| HR (1) | HRP20010042B1 (enExample) |
| HU (1) | HUP0102429A3 (enExample) |
| ID (1) | ID27343A (enExample) |
| IL (2) | IL140381A0 (enExample) |
| NO (1) | NO329193B1 (enExample) |
| NZ (1) | NZ508982A (enExample) |
| PL (1) | PL197722B1 (enExample) |
| PT (1) | PT1088077E (enExample) |
| SI (1) | SI1088077T1 (enExample) |
| TR (1) | TR200100350T2 (enExample) |
| UA (1) | UA77146C2 (enExample) |
| WO (1) | WO1999066045A1 (enExample) |
| ZA (1) | ZA200100241B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109735552A (zh) * | 2019-02-27 | 2019-05-10 | 苏州世诺生物技术有限公司 | 禽新城疫病毒新型基因工程亚单位疫苗 |
| CN110018304A (zh) * | 2019-05-15 | 2019-07-16 | 河南省农业科学院 | 一种新城疫抗体阻断检测试纸 |
| CN111771000A (zh) * | 2018-02-28 | 2020-10-13 | 瑞泽恩制药公司 | 用于鉴定病毒污染物的系统和方法 |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0974660A1 (en) | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| US6146642A (en) * | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
| US10383936B2 (en) * | 1999-05-05 | 2019-08-20 | University Of Maryland, College Park | Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector |
| US7244558B1 (en) * | 1999-05-05 | 2007-07-17 | University Of Maryland | Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines |
| EP1074614B1 (en) * | 1999-07-27 | 2004-07-07 | Akzo Nobel N.V. | A recombinant Newcastle disease virus for in ovo vaccination |
| CA2312626A1 (en) | 1999-07-27 | 2001-01-27 | Akzo Nobel N.V. | A recombinant newcastle disease virus as an embryo vaccine |
| ATE437223T1 (de) * | 2000-06-23 | 2009-08-15 | Intervet Int Bv | Attenuiertes bovines respiratorisches syncytialvirus |
| ATE352557T1 (de) | 2000-11-02 | 2007-02-15 | Intervet Int Bv | Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff |
| KR100437888B1 (ko) * | 2001-07-30 | 2004-07-03 | 주식회사 인트론바이오테크놀로지 | 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법 |
| US7615209B2 (en) | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
| IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
| DE60114420T2 (de) * | 2001-10-04 | 2006-07-13 | Centrum Voor Onderzoek In Diergeneeskunde En Agrochemie | Abgeschwächter Mutantenstamm eines Virus der Newcastle-Krankheit für eine in Ovo Impfung und dessen Benutzung |
| JP2005518209A (ja) * | 2002-02-21 | 2005-06-23 | マウント シナイ スクール オブ メディシン | 組換えマイナス鎖ウイルスｒｎａ発現系およびワクチン |
| TW200502402A (en) * | 2002-12-06 | 2005-01-16 | Wyeth Corp | Escape mutants of newcastle disease virus as marker vaccines |
| US7132291B2 (en) | 2003-05-05 | 2006-11-07 | Dow Agro Sciences Llc | Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
| AU2004235800B2 (en) * | 2003-05-05 | 2010-02-18 | Dow Agrosciences Llc | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
| CA2503774C (en) | 2003-06-20 | 2007-09-25 | Microbix Biosystems Inc. | Improvements in virus production |
| US7527638B2 (en) | 2003-12-16 | 2009-05-05 | Depuy Spine, Inc. | Methods and devices for minimally invasive spinal fixation element placement |
| MY146476A (en) | 2004-06-24 | 2012-08-15 | Boehringer Ingelheim Vetmed | Method of diagnosing lawsonia intracellularis |
| GB0423681D0 (en) * | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
| JP2008519590A (ja) | 2004-11-12 | 2008-06-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 組換えニューカッスル病ウィルス |
| US7871626B2 (en) * | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| EA016217B1 (ru) | 2005-12-02 | 2012-03-30 | Маунт Синай Скул Оф Медсин | Химерные вирусы, представляющие неприродные поверхностные белки, и их применение |
| KR20090007706A (ko) * | 2006-03-15 | 2009-01-20 | 인터벳 인터내셔널 비.브이. | 조류 인플루엔자 바이러스의 ｈ5 헤마글루티닌을 발현하는 재조합 뉴캐슬병 바이러스 |
| AU2007226555B2 (en) * | 2006-03-15 | 2012-07-05 | Intervet International B.V. | Recombinant Mononegaviral virus vectors |
| KR100776398B1 (ko) * | 2006-03-23 | 2007-11-28 | 주식회사 고려비엔피 | 조류 ｈｎ 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스 |
| KR100801180B1 (ko) | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| KR100874256B1 (ko) | 2007-02-12 | 2008-12-16 | 대한민국 | 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도 |
| KR100955502B1 (ko) * | 2007-11-30 | 2010-04-30 | 대한민국 | 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도 |
| EP2085092A1 (en) | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| US7794714B2 (en) * | 2008-03-14 | 2010-09-14 | The United States Of America As Represented By The Secretary Of Agriculture | Newcastle disease virus monoclonal antibodies |
| US20090258035A1 (en) * | 2008-03-21 | 2009-10-15 | The United States Of America, As Represented By The Secretary Of Agriculture | Avian virus vaccines and uses thereof |
| AU2008364200B2 (en) * | 2008-11-19 | 2016-01-28 | Laboratorio Avi-Mex, S.A. De C.V. | Recombinant inactivated viral vector vaccine |
| EP2987856B1 (en) | 2009-02-05 | 2018-07-25 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| MX2012002114A (es) | 2009-08-21 | 2012-08-08 | Univ Georgia | Vacuna de paramixovirus aviar recombinante y metodo para hacerla y usarla. |
| US20110110975A1 (en) * | 2009-11-06 | 2011-05-12 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| ES2380289T3 (es) | 2009-11-30 | 2012-05-10 | United Cancer Research Institute | Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer |
| US9956281B2 (en) | 2011-05-04 | 2018-05-01 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| JP6293664B2 (ja) | 2011-10-27 | 2018-03-14 | ウェルスタット オフサルミクス コーポレイション | 桿体由来錐体生存因子をコードするベクター |
| WO2013082327A1 (en) | 2011-11-30 | 2013-06-06 | Merial Limited | Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof |
| KR101374192B1 (ko) * | 2011-12-21 | 2014-03-14 | 대한민국 | 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액 |
| WO2014158811A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| CN104059942B (zh) * | 2013-03-20 | 2016-12-28 | 湖北省农业科学院畜牧兽医研究所 | 新城疫病毒耐热活疫苗载体系统及其应用 |
| US20140341950A1 (en) * | 2013-05-15 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Recombinant avian paramyxovirus vaccine and method for making and using thereof |
| SG11201607130RA (en) | 2014-02-27 | 2016-09-29 | Viralytics Ltd | Combination method for treatment of cancer |
| US10780158B2 (en) | 2015-11-16 | 2020-09-22 | Georgia State University Research Foundation, Inc. | Tunable vaccine platform against pathogens of the paramyxovirus family |
| RU2769406C2 (ru) | 2016-02-03 | 2022-03-31 | СиДжи ДИСКАВЕРИ, ИНК. | Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании |
| US10063211B2 (en) * | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| US10196616B2 (en) | 2017-02-15 | 2019-02-05 | The United States Of America, As Represented By The Secretary Of Agriculture | Altered avian virus for in-ovo inoculation and methods of use thereof |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2020014591A1 (en) * | 2018-07-13 | 2020-01-16 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| US12391957B2 (en) | 2018-08-17 | 2025-08-19 | Icahn School Of Medicine At Mount Sinai | Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease |
| CN110240635B (zh) * | 2019-06-10 | 2022-04-22 | 华中农业大学 | 检测新城疫病毒抗体的多肽及其elisa检测试剂盒 |
| CN110257562A (zh) * | 2019-07-31 | 2019-09-20 | 河北农业大学 | 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用 |
| US11334671B2 (en) * | 2019-10-14 | 2022-05-17 | International Business Machines Corporation | Adding adversarial robustness to trained machine learning models |
| KR102154796B1 (ko) * | 2019-10-18 | 2020-09-22 | 주식회사 바이오포아 | 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신 |
| CN110938711A (zh) * | 2019-12-20 | 2020-03-31 | 河北农业大学 | 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法 |
| CN111334528B (zh) * | 2020-03-20 | 2022-02-18 | 山东农业大学 | 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用 |
| CN112048484A (zh) * | 2020-07-27 | 2020-12-08 | 华南农业大学 | 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗 |
| CN114214338B (zh) * | 2021-08-26 | 2023-02-03 | 扬州大学 | 猪源piv5全长感染性克隆及其制备方法和应用 |
| WO2024206928A1 (en) | 2023-03-30 | 2024-10-03 | Pharma Cinq, Llc | VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
| ATE257175T1 (de) | 1994-07-18 | 2004-01-15 | Conzelmann Karl Klaus Prof Dr | Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus |
| EP0832197A4 (en) * | 1995-06-07 | 2002-10-16 | Syntro Corp | RECOMBINANT AVIAN SMALLPOX VIRUS AND USES THEREOF |
| ATE181112T1 (de) * | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
| EP0839912A1 (en) * | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| EP0974660A1 (en) | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
-
1998
- 1998-06-19 EP EP98202054A patent/EP0974660A1/en not_active Withdrawn
-
1999
- 1999-06-17 IL IL14038199A patent/IL140381A0/xx active IP Right Grant
- 1999-06-17 UA UA2001010408A patent/UA77146C2/uk unknown
- 1999-06-17 CN CNA2008100921449A patent/CN101275142A/zh active Pending
- 1999-06-17 DK DK99926984T patent/DK1088077T3/da active
- 1999-06-17 EP EP99926984A patent/EP1088077B2/en not_active Expired - Lifetime
- 1999-06-17 CN CN99809714A patent/CN1314942A/zh active Pending
- 1999-06-17 HR HR20010042A patent/HRP20010042B1/xx not_active IP Right Cessation
- 1999-06-17 CZ CZ20004707A patent/CZ300760B6/cs not_active IP Right Cessation
- 1999-06-17 HU HU0102429A patent/HUP0102429A3/hu unknown
- 1999-06-17 JP JP2000554854A patent/JP2002518012A/ja not_active Withdrawn
- 1999-06-17 EA EA200100057A patent/EA004796B1/ru not_active IP Right Cessation
- 1999-06-17 PL PL348300A patent/PL197722B1/pl not_active IP Right Cessation
- 1999-06-17 AT AT99926984T patent/ATE367442T1/de active
- 1999-06-17 NZ NZ508982A patent/NZ508982A/en unknown
- 1999-06-17 WO PCT/NL1999/000377 patent/WO1999066045A1/en not_active Ceased
- 1999-06-17 SI SI9930990T patent/SI1088077T1/sl unknown
- 1999-06-17 PT PT99926984T patent/PT1088077E/pt unknown
- 1999-06-17 ID IDW20010146A patent/ID27343A/id unknown
- 1999-06-17 AU AU43991/99A patent/AU754844B2/en not_active Ceased
- 1999-06-17 KR KR1020007014397A patent/KR20010053000A/ko not_active Ceased
- 1999-06-17 TR TR2001/00350T patent/TR200100350T2/xx unknown
- 1999-06-17 BR BR9911383-0A patent/BR9911383A/pt not_active IP Right Cessation
- 1999-06-17 CA CA002334165A patent/CA2334165A1/en not_active Abandoned
- 1999-06-17 DE DE69936585T patent/DE69936585T2/de not_active Expired - Lifetime
- 1999-06-17 ES ES99926984T patent/ES2291029T3/es not_active Expired - Lifetime
- 1999-06-18 AR ARP990102948A patent/AR020091A1/es not_active Application Discontinuation
-
2000
- 2000-12-15 NO NO20006406A patent/NO329193B1/no not_active IP Right Cessation
- 2000-12-18 IL IL140381A patent/IL140381A/en not_active IP Right Cessation
- 2000-12-19 US US09/741,744 patent/US6719979B2/en not_active Expired - Fee Related
-
2001
- 2001-01-09 ZA ZA2001/00241A patent/ZA200100241B/en unknown
-
2004
- 2004-02-26 US US10/788,232 patent/US7332169B2/en not_active Expired - Fee Related
- 2004-04-15 US US10/824,782 patent/US7547442B2/en not_active Expired - Fee Related
-
2005
- 2005-12-01 JP JP2005347888A patent/JP2006141398A/ja active Pending
-
2009
- 2009-02-04 JP JP2009023349A patent/JP2009261387A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111771000A (zh) * | 2018-02-28 | 2020-10-13 | 瑞泽恩制药公司 | 用于鉴定病毒污染物的系统和方法 |
| CN109735552A (zh) * | 2019-02-27 | 2019-05-10 | 苏州世诺生物技术有限公司 | 禽新城疫病毒新型基因工程亚单位疫苗 |
| CN110018304A (zh) * | 2019-05-15 | 2019-07-16 | 河南省农业科学院 | 一种新城疫抗体阻断检测试纸 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101275142A (zh) | 新城疫病毒感染性克隆、疫苗及诊断分析 | |
| RU2658439C2 (ru) | Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц | |
| CN102533674B (zh) | 表达禽流感病毒血凝素基因的重组鸭病毒性肠炎病毒疫苗株及其构建方法和应用 | |
| CN102373180B (zh) | 表达禽流感病毒血凝素(ha)基因的重组鸭病毒性肠炎病毒疫苗株及其构建方法和应用 | |
| JP2004517612A (ja) | マーカーワクチンとしての、組み換えニューカッスル病ウイルス核タンパク質の突然変異体 | |
| CN110904058B (zh) | 重组鸭瘟病毒疫苗及其构建方法和应用 | |
| US20100008948A1 (en) | Recombinant herpesvirus useful in vaccine production | |
| AU729518B2 (en) | Recombinant fowlpox viruses and uses thereof | |
| MXPA00012787A (en) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: AGRICULTURAL RESEARCH FOUNDATION Free format text: FORMER OWNER: ID-LELYSTAD INSTITUTE OF ANIMAL BREEDING AND ANIMAL HEALTH CO., LTD. Effective date: 20100413 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: LELYSTAD,HOLLAND TO: WAGENINGEN,NETHERLAND |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100413 Address after: Wageningen Applicant after: The Agricultural Research Foundation Address before: Holland Lelystad Applicant before: ID-Lelistad Animal Breeding & Animal Health Inst N.V. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20081001 |